Document Detail

Automated analysis of delayed emesis in the telemetered ferret: Detection of synergistic effects of aprepitant and ondansetron.
MedLine Citation:
PMID:  24750138     Owner:  NLM     Status:  Publisher    
Nausea and vomiting are common side effects of cancer chemotherapy. We have previously described a model in the ferret where delayed emesis can be measured automatically using telemetry. This study was designed to examine the sensitivity of this automated emesis model for detecting moderate and/or additive pharmacological effects by investigating low-dose effects of aprepitant alone or in combination with ondansetron. Ferrets implanted with telemetry devices (Data Sciences International) were orally treated with aprepitant (0.03 mg/kg) and/or ondansetron (0.3 mg/kg) and then challenged with cisplatin (8 mg/kg, i.p.). Abdominal pressure was recorded in unrestrained animals from 18 to 72 hours post-challenge and the pressure signals were automatically analyzed using adapted software (Emka Technologies). Ondansetron administered alone 1 hour before cisplatin challenge had no significant effects on the delayed emesis phase. Once daily treatment with aprepitant (2 hours before cisplatin and then, 24 and 48 hours after cisplatin challenge) slightly reduced the total number of emetic events (-32%, NS). When administered together, aprepitant and ondansetron exhibited synergistic effects on delayed phase emesis. The combined treatment markedly and significantly decreased the mean number of emetic events recorded between 24 and 54 hours after cisplatin dosing (-75%, p<0.05) and the total number of emetic events (-56%, p<0.05). Our results demonstrate that the automated cisplatin-induced emesis model in the ferret is sensitive enough to detect the synergistic effects of aprepitant and ondansetron in combination, creating new and important perspectives for the evaluation of combined therapy in the reduction of side-effects of cancer chemotherapy. This article is protected by copyright. All rights reserved.
Sonia Goineau; Philippe Guillaume; Laurence Barrais; Vincent Castagné
Related Documents :
23211088 - Novel, biocompatible, and disease modifying vip nanomedicine for rheumatoid arthritis.
1699908 - Reduction of the local toxicity of intraperitoneal chemotherapy; an experimental model.
10338218 - Structured versus long-chain triglycerides: a safety, tolerance, and efficacy randomize...
23069308 - Generalized hailey-hailey disease triggered by nonsteroidal antiinflammatory drug-induc...
885158 - Amphetamine discrimination as a test for anti-parkinsonism drugs.
4027148 - The acute haemodynamic effects of oral nicardipine.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2014-4-19
Journal Detail:
Title:  Fundamental & clinical pharmacology     Volume:  -     ISSN:  1472-8206     ISO Abbreviation:  Fundam Clin Pharmacol     Publication Date:  2014 Apr 
Date Detail:
Created Date:  2014-4-22     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8710411     Medline TA:  Fundam Clin Pharmacol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
This article is protected by copyright. All rights reserved.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The Arabidopsis thaliana mitogen-activated protein kinases MPK3 and MPK6 target a subclass of 'VQ-mo...
Next Document:  Asymptomatic Traumatic Diaphragmatic Hernia Discovered During an Aortic Valve Replacement.